Jefferies

EQS-News: Final offer price for DOUGLAS AG shares set at 26.00 euro per share

Retrieved on: 
Wednesday, April 10, 2024
Deutsche Bank, Citigroup, RBI, Growth, Frankfurt Stock Exchange, Goldman Sachs, WKN, UBS, Intesa Sanpaolo, UniCredit, IPO, BNP Paribas, Investment, Jefferies, LBBW, CVC Capital Partners, DOU, Security (finance)

CVC Capital Partners and the Kreke family remain main indirect shareholders after the IPO and do not sell any shares at the IPO.

Key Points: 
  • CVC Capital Partners and the Kreke family remain main indirect shareholders after the IPO and do not sell any shares at the IPO.
  • The total offer size amounts to around 890 million euro with gross proceeds for DOUGLAS AG of around 850 million euro, which corresponds to a market capitalization of DOUGLAS AG of around 2.8 billion euro.
  • Sander van der Laan, CEO DOUGLAS Group, said: “The significant investor interest in the DOUGLAS Group underlines the exceptional work our team has accomplished in recent months.
  • The shares of DOUGLAS AG are expected to be trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange from March 21, 2024, on.

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Retrieved on: 
Tuesday, April 9, 2024
ACRV, Exchange, Health, Intelligence, Patient, Neoplasm, Paradigm, Research, AP3, Sale, Security (finance), Prospectus, Investment, Therapy, PIPE, Jefferies, Machine learning, Medicine

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.

Key Points: 
  • Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
  • The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
  • “We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Jefferies acted as the exclusive placement agent in the private placement.

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

Retrieved on: 
Monday, April 8, 2024
Jefferies, Cancer, Conference, CATX, Radiopharmaceutical

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April.

Key Points: 
  • SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April.
  • Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthruption Conference, on April 9, 2024 at 2:40 p.m.
  • Management will be available for one-on-one investor meetings at the conference.
  • A replay of the Jefferies presentation will be archived for 90 days and available through the Investors page on the Perspective website.

Marex Group plc Announces Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Tuesday, March 26, 2024
Attention, Seventh Avenue, Madison Avenue, Goldman Sachs, 4th floor, Form, Keefe, Bruyette & Woods, Marex, Sale, Prospectus, Broadridge Financial Solutions, Jefferies, Equity capital markets, Jefferies Group, Barclays, Cryptocurrency

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.
  • The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Barclays, Goldman Sachs & Co. LLC, Jefferies, and Keefe, Bruyette & Woods, a Stifel Company, are acting as joint lead book-running managers for the proposed offering.
  • A registration statement relating to these securities has been filed with the SEC but has not yet become effective.

ARIS MINING ANNOUNCES APPOINTMENT OF RICHARD ORAZIETTI AS CFO AND OLIVER DACHSEL AS SVP, CAPITAL MARKETS

Retrieved on: 
Monday, April 8, 2024
Growth, Gold, Metal, Controller, Senior, Jefferies, Capital market, TSX, Goldcorp, Treasury, ARIS, Cryptocurrency

VANCOUVER, BC, April 8, 2024 /PRNewswire/ - Aris Mining Corporation (Aris Mining or the Company) (TSX: ARIS) (NYSE-A: ARMN) announces the appointment of Richard Orazietti as Chief Financial Officer, effective May 16, 2024, and Oliver Dachsel as Senior Vice President, Capital Markets.

Key Points: 
  • VANCOUVER, BC, April 8, 2024 /PRNewswire/ - Aris Mining Corporation (Aris Mining or the Company) (TSX: ARIS) (NYSE-A: ARMN) announces the appointment of Richard Orazietti as Chief Financial Officer, effective May 16, 2024, and Oliver Dachsel as Senior Vice President, Capital Markets.
  • Neil Woodyer, CEO of Aris Mining, commented "I am delighted to introduce Oliver and Richard as valuable additions to Aris Mining's management team.
  • Richard brings experience in corporate development, financial planning and reporting within the gold mining sector, having been the Senior Vice President, Treasury and Controller of Goldcorp.
  • Oliver has deep industry connections and corporate finance expertise, having most recently served as a Managing Director on Jefferies' metals & mining investment banking team in New York.

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, BofA Securities, Madison Avenue, Form, Telephone, Patient, SAN, Sale, Attention, Cancer, Security (finance), Therapy, OrbiMed, Jefferies, IPSC, State Street, Jefferies Group

The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.

Key Points: 
  • The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
  • The gross proceeds from the underwritten offering and private placement are expected to be approximately $100.0 million before deducting underwriting discounts and commissions and other offering expenses.
  • BofA Securities, Jefferies, and Leerink Partners are acting as the joint bookrunning managers for the underwritten offering.
  • A final prospectus supplement relating to and describing the terms of the underwritten offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Retrieved on: 
Tuesday, March 19, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.

Key Points: 
  • The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.
  • The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million.
  • Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.

Madrigal Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Monday, March 18, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the shares in the proposed offering are to be sold by Madrigal.
  • Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI, Piper Sandler, UBS Investment Bank and Citizens JMP are acting as joint bookrunning managers of the proposed offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Collective Audience Appoints Silicon Valley/Tech Finance Veteran, Josh Tanzer, to Advisor Collective

Retrieved on: 
Thursday, March 14, 2024
Noguchi Museum, Automation, TD Ameritrade, Funding, Tanzer, University, Growth, Fintech, Salesforce, Adtech (company), Commerce, AI, Credit Suisse, IPO, MLOps, DevOps, Vonage, M&A, Whitney Museum, Exodus Communications, Jefferies, B2B, Martech, Commvault, National Committee

Tanzer is the founder and managing partner of Principia Growth, a technology growth equity investment firm based in Los Angeles and New York.

Key Points: 
  • Tanzer is the founder and managing partner of Principia Growth, a technology growth equity investment firm based in Los Angeles and New York.
  • As a mid-to-late-stage growth investor, Principia monitors a broad spectrum of emerging technologies and invests in entrepreneurs who are building enduring companies.
  • “Josh expands the breadth and depth of our Advisor Collective with extraordinary knowledge and experience across finance, cloud infrastructure, AI, fintech, technology investing and M&A, along with deep Wallstreet and tech industry relationships,” stated Collective Audience CEO, Peter Bordes.
  • To learn more about Josh Tanzer and his vision for the future of the industry, visit the Collective Audience Blog here .

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Retrieved on: 
Tuesday, March 12, 2024
BofA Securities, Montgomery Street, Exercise, Madison Avenue, Atopic dermatitis, Goldman Sachs, Telephone, SAN, Chronic obstructive pulmonary disease, Sale, Attention, Security (finance), Lexington Avenue, Asthma, Suite, Apsis, Prospectus, Therapy, Jefferies, Jefferies Group

The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
  • All of the shares were offered by Apogee.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel acted as joint book-running managers for the offering.
  • Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on March 7, 2024.